We continue our series in the Biologics campaign – now it is about Estrogen receptors (ERs).
Estrogen acts a crucial role in regulating different physiological and pathological actions in organisms of males and females. Several endogenous estrogen ligands are associated with health problems in pre and postmenopausal women. The estrogen receptors (ERs), ERα and ERβ, are involved in mediating the effects of endogenous estrogen, while non-genomic cytoplasmic pathways also modulate cell growth and apoptosis. Breast cancer is heavily influenced by estrogen, which plays a fundamental role in its development and progression. One of the challenges in developing drugs against breast cancer is mutations and further resistance to drugs over time.
You can find more about ERs signaling studies here.
However, recent success in drug development has shown promise in overcoming mutation challenges. This February elacestrant, which is a selective estrogen receptor degrader (SERD) of ER-positive/HER2-negative advanced breast cancer was approved by FDA. Unlike traditional drugs that block estrogen from receptors binding, elacestrant works by degrading the ERs themselves. This approach has shown promise in overcoming resistance to traditional drugs and has shown efficacy in clinical trials. The development of elacestrant and other innovative drugs gives hope for improving breast cancer treatment.
More information about this research is here.
